IL2 and neoplasm: The goal of a subsequent proof-of-concept phase II clinical trial is to analyze the efficacy of TKD/IL-2-activated NK cells in NSCLC patients following radiochemotherapy as this has been shown to enhance the density of Hsp70 membrane expression on tumor cells (unpublished observations).